Last reviewed · How we verify
CarVeDilol-SR (Slow Release)
Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.
At a glance
| Generic name | CarVeDilol-SR (Slow Release) |
|---|---|
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | Beta-blocker with alpha-1 blocking activity |
| Target | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Carvedilol blocks beta-1 and beta-2 adrenergic receptors as well as alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and vasculature. The slow-release formulation provides sustained drug delivery over an extended period, allowing for once-daily dosing. This combination of effects reduces cardiac oxygen demand, lowers blood pressure, and improves cardiac efficiency in heart failure and hypertension.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Left ventricular dysfunction following myocardial infarction
- Angina pectoris
Common side effects
- Dizziness
- Fatigue
- Bradycardia
- Hypotension
- Hyperglycemia
- Bronchospasm
Key clinical trials
- Carvedilol in HF With Preserved EF (PHASE4)
- Immediate Release Versus Slow Release Carvedilol in Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CarVeDilol-SR (Slow Release) CI brief — competitive landscape report
- CarVeDilol-SR (Slow Release) updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI